Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CRLF3 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | Q8IUI8 |
| Other Accession | Q9Z2L7, NP_057070.3 |
| Reactivity | Human |
| Predicted | Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 49766 Da |
| Antigen Region | 305-331 aa |
| Gene ID | 51379 |
|---|---|
| Other Names | Cytokine receptor-like factor 3, Cytokine receptor-like molecule 9, CREME-9, Cytokine receptor-related protein 4, Type I cytokine receptor-like factor p48, CRLF3, CREME9, CRLM9, CYTOR4, P48 |
| Target/Specificity | This CRLF3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 305-331 amino acids from the C-terminal region of human CRLF3. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | CRLF3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CRLF3 |
|---|---|
| Synonyms | CREME9, CRLM9, CYTOR4, P48 |
| Function | May play a role in the negative regulation of cell cycle progression. |
| Cellular Location | Cytoplasm. Note=The EGFP- and MYC-tagged protein has been shown to be cytoplasmic |
| Tissue Location | Expressed in several embryonic and adult tissues, including adult and fetal brain, liver, spleen and pancreas. Expressed in adult, but not fetal kidney. Expressed in skin and squamous cell carcinoma (SCC) and in several other cancer types. Also detected in lesion actinic keratosis (AK). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CRLF3 (Cytokine receptor-like factor 3) contains one fibronectin type-III domain. It is expressed in skin and squamous cell carcinoma (SCC) and in lesion actinic keratosis (AK).
References
Johnatty, S.E., et al. PLoS Genet. 6 (7), E1001016 (2010) :
Zhao, J., et al. BMC Med. Genet. 11, 96 (2010) :
Yang, F., et al. Int. J. Biochem. Cell Biol. 41(11):2240-2250(2009)
Visser, R., et al. Am. J. Med. Genet. A 149A (4), 806-808 (2009) :
Gudbjartsson, D.F., et al. Nat. Genet. 40(5):609-615(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
